0. Advocacy Graphic

The Voice of Addiction Medicine

 Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care

ASAM's Advocacy Principles

Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of addiction medicine so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to coordinated, comprehensive care
Advocacy Homepage HR 6 Graphic

It's time we treat addiction like other chronic diseases 


Advocacy Committees & Councils

ASAM's advocacy could not happen if not for the dedicated effort of our members.

0. Find a Policy Statement 1 - cropped

Public Policy Statements

Learn about ASAM's position on current policy issues.

Teamwork - smallest


ASAM is proud to work collaboratively with others to improve the lives of those living with addiction.
0. Advocacy Toolkits

Advocacy Toolkits

ASAM provides toolkits to help you advocate for public policies that advance addiction medicine and promote access to treatment

Legislative Tracker Graphic


ASAM Endorses the Cannabidiol and Marijuana Research Expansion Act

by | Jul 01, 2019


On June 27, Senator Dianne Feinstein (D-CA), Senator Chuck Grassley (R-IA), and Senator Brian Schatz (D-HI) introduced the Cannabidiol and Marijuana Research Expansion Act, which would reduce barriers to the study of cannabis and its compounds, including cannabidiol (CBD), for use in the treatment of medical conditions. ASAM endorsed the bill in a letter from the Friends of the National Institute on Drug Abuse in May. There is a significant lack of research and understanding surrounding the effects of cannabis derived substances on both adolescents and adults. As an organization committed to advocating for the use of evidence-based treatment, ASAM is excited for the increased research into cannabis related substances that this bill would encourage. 


The bill improves interagency efficiency by requiring that the Department of Justice (DoJ) approve applications for Schedule I registration if the researchers’ protocols have been reviewed and approved by other federal science agencies, and adequate security measures exist to prevent abuse and diversion. The bill additionally requires that the process for approving applications for Schedule I registration, as well as the process for approving requests to increase the quantity of a substance being used for an approved research protocol, be expedited. Furthermore, the bill would authorize medical and osteopathic schools, research universities, and pharmaceutical companies to manufacture their own cannabis to conduct research. All of these provisions would greatly improve the medical communities ability to understand the potential treatment benefits, as well as harms, related to cannabis derived substances.


Read the bill text here.


Read the Friends of NIDA letter here.